Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cataract Extraction | 33 | 2024 | 465 | 8.470 |
Why?
|
Cataract | 43 | 2024 | 827 | 8.350 |
Why?
|
Retinopathy of Prematurity | 36 | 2023 | 432 | 6.850 |
Why?
|
Lens Implantation, Intraocular | 32 | 2022 | 190 | 6.720 |
Why?
|
Lenses, Intraocular | 19 | 2022 | 138 | 6.300 |
Why?
|
Aphakia, Postcataract | 18 | 2022 | 52 | 4.460 |
Why?
|
Glaucoma | 14 | 2024 | 1182 | 3.660 |
Why?
|
Aphakia | 7 | 2023 | 26 | 2.920 |
Why?
|
Hydrophthalmos | 3 | 2023 | 24 | 2.390 |
Why?
|
Intraocular Pressure | 14 | 2024 | 1288 | 2.120 |
Why?
|
Glaucoma Drainage Implants | 3 | 2022 | 106 | 2.100 |
Why?
|
Retinal Neoplasms | 7 | 2024 | 146 | 2.030 |
Why?
|
Refraction, Ocular | 10 | 2022 | 179 | 2.020 |
Why?
|
Refractive Errors | 8 | 2022 | 145 | 1.950 |
Why?
|
Retinoblastoma | 6 | 2024 | 317 | 1.830 |
Why?
|
Ophthalmology | 13 | 2021 | 549 | 1.790 |
Why?
|
Myopia | 5 | 2022 | 245 | 1.650 |
Why?
|
Strabismus | 10 | 2022 | 317 | 1.640 |
Why?
|
Visual Acuity | 25 | 2023 | 2642 | 1.610 |
Why?
|
Optics and Photonics | 5 | 2022 | 304 | 1.520 |
Why?
|
Trabeculectomy | 2 | 2022 | 174 | 1.430 |
Why?
|
Academies and Institutes | 11 | 2021 | 319 | 1.400 |
Why?
|
Lens, Crystalline | 4 | 2022 | 388 | 1.320 |
Why?
|
Amblyopia | 3 | 2022 | 150 | 1.290 |
Why?
|
Contact Lenses | 4 | 2019 | 138 | 1.280 |
Why?
|
Phacoemulsification | 3 | 2022 | 149 | 1.250 |
Why?
|
Pseudophakia | 8 | 2022 | 60 | 1.160 |
Why?
|
Xanthomatosis, Cerebrotendinous | 2 | 2024 | 9 | 1.120 |
Why?
|
Infant, Newborn | 55 | 2023 | 26183 | 0.980 |
Why?
|
Persistent Hyperplastic Primary Vitreous | 1 | 2023 | 7 | 0.900 |
Why?
|
Infant | 56 | 2024 | 36055 | 0.900 |
Why?
|
Eye Abnormalities | 2 | 2023 | 241 | 0.840 |
Why?
|
Child | 49 | 2024 | 79818 | 0.810 |
Why?
|
Child, Preschool | 40 | 2024 | 42062 | 0.760 |
Why?
|
Biometry | 7 | 2023 | 559 | 0.730 |
Why?
|
Angiogenesis Inhibitors | 7 | 2023 | 2047 | 0.720 |
Why?
|
Laser Coagulation | 7 | 2024 | 329 | 0.710 |
Why?
|
Lens Capsule, Crystalline | 1 | 2019 | 39 | 0.670 |
Why?
|
Eye Diseases | 4 | 2016 | 651 | 0.660 |
Why?
|
Orthokeratologic Procedures | 1 | 2018 | 6 | 0.650 |
Why?
|
Technology Assessment, Biomedical | 7 | 2021 | 306 | 0.630 |
Why?
|
Gestational Age | 22 | 2023 | 3565 | 0.620 |
Why?
|
Eyeglasses | 1 | 2019 | 137 | 0.600 |
Why?
|
Infant, Premature, Diseases | 2 | 2021 | 708 | 0.600 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2019 | 3480 | 0.600 |
Why?
|
Vision, Low | 1 | 2020 | 163 | 0.600 |
Why?
|
Vision Disorders | 5 | 2022 | 1084 | 0.590 |
Why?
|
Eye Injuries | 1 | 2020 | 227 | 0.570 |
Why?
|
Retinal Diseases | 2 | 2021 | 702 | 0.560 |
Why?
|
Optic Disk | 1 | 2021 | 421 | 0.560 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2020 | 666 | 0.550 |
Why?
|
Ectopia Lentis | 2 | 2013 | 20 | 0.540 |
Why?
|
Neonatal Screening | 4 | 2020 | 594 | 0.540 |
Why?
|
Dacryocystorhinostomy | 3 | 2008 | 78 | 0.520 |
Why?
|
Humans | 125 | 2024 | 758406 | 0.510 |
Why?
|
Infant, Premature | 14 | 2023 | 2092 | 0.500 |
Why?
|
Retrospective Studies | 38 | 2024 | 80168 | 0.500 |
Why?
|
Photography | 2 | 2010 | 530 | 0.500 |
Why?
|
Melphalan | 2 | 2014 | 420 | 0.500 |
Why?
|
Postoperative Complications | 11 | 2023 | 15637 | 0.490 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2014 | 136 | 0.480 |
Why?
|
Nasolacrimal Duct | 2 | 2008 | 79 | 0.470 |
Why?
|
Intravitreal Injections | 7 | 2023 | 384 | 0.470 |
Why?
|
Pupil Disorders | 1 | 2014 | 32 | 0.470 |
Why?
|
Infusions, Intra-Arterial | 1 | 2014 | 221 | 0.470 |
Why?
|
Eye | 4 | 2022 | 710 | 0.460 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2013 | 25 | 0.440 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2014 | 617 | 0.420 |
Why?
|
Glaucoma, Open-Angle | 1 | 2019 | 734 | 0.420 |
Why?
|
Diagnostic Techniques, Ophthalmological | 2 | 2016 | 250 | 0.410 |
Why?
|
Retinal Vessels | 2 | 2016 | 836 | 0.410 |
Why?
|
gamma-Crystallins | 1 | 2011 | 9 | 0.400 |
Why?
|
Follow-Up Studies | 20 | 2023 | 39059 | 0.400 |
Why?
|
Hyperopia | 1 | 2012 | 41 | 0.400 |
Why?
|
Ophthalmologic Surgical Procedures | 3 | 2021 | 353 | 0.400 |
Why?
|
Weight Gain | 4 | 2021 | 2346 | 0.390 |
Why?
|
Nystagmus, Pathologic | 1 | 2012 | 105 | 0.390 |
Why?
|
Endoscopy | 4 | 2024 | 1834 | 0.380 |
Why?
|
Mydriatics | 4 | 2022 | 67 | 0.370 |
Why?
|
Endothelium, Corneal | 1 | 2013 | 214 | 0.360 |
Why?
|
Propoxycaine | 1 | 2010 | 6 | 0.360 |
Why?
|
Sclera | 2 | 2024 | 190 | 0.360 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2013 | 351 | 0.350 |
Why?
|
Lasers, Semiconductor | 1 | 2010 | 41 | 0.350 |
Why?
|
Benchmarking | 1 | 2016 | 1042 | 0.350 |
Why?
|
Eye Neoplasms | 1 | 2012 | 306 | 0.340 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 586 | 0.330 |
Why?
|
Axial Length, Eye | 2 | 2023 | 33 | 0.330 |
Why?
|
Ciliary Body | 2 | 2024 | 166 | 0.330 |
Why?
|
Infant, Very Low Birth Weight | 7 | 2016 | 406 | 0.330 |
Why?
|
Anterior Eye Segment | 1 | 2010 | 141 | 0.320 |
Why?
|
Retinoscopy | 3 | 2020 | 26 | 0.310 |
Why?
|
Schools | 1 | 2017 | 1482 | 0.310 |
Why?
|
Mucocele | 1 | 2008 | 51 | 0.310 |
Why?
|
Optic Nerve Neoplasms | 1 | 2008 | 45 | 0.310 |
Why?
|
Hemangioma | 1 | 2013 | 727 | 0.310 |
Why?
|
Birth Weight | 5 | 2023 | 2097 | 0.310 |
Why?
|
Fluprednisolone | 2 | 2016 | 6 | 0.280 |
Why?
|
Treatment Outcome | 19 | 2023 | 64378 | 0.280 |
Why?
|
Atropine | 2 | 2017 | 244 | 0.270 |
Why?
|
Quality Indicators, Health Care | 1 | 2016 | 1797 | 0.270 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3242 | 0.270 |
Why?
|
Female | 55 | 2024 | 390323 | 0.270 |
Why?
|
Prosthesis Implantation | 2 | 2021 | 590 | 0.260 |
Why?
|
Communication | 1 | 2020 | 3846 | 0.250 |
Why?
|
Prednisolone | 2 | 2016 | 326 | 0.250 |
Why?
|
Male | 52 | 2024 | 358747 | 0.250 |
Why?
|
Suture Techniques | 2 | 2021 | 788 | 0.250 |
Why?
|
Oxygen | 3 | 2021 | 4191 | 0.240 |
Why?
|
Cornea | 2 | 2023 | 1326 | 0.240 |
Why?
|
Risk Factors | 18 | 2023 | 73809 | 0.230 |
Why?
|
Cholestanol | 1 | 2023 | 5 | 0.220 |
Why?
|
Neurofibromatosis 1 | 1 | 2008 | 560 | 0.220 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2006 | 399 | 0.220 |
Why?
|
Soft Tissue Neoplasms | 1 | 2012 | 1152 | 0.210 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 3339 | 0.210 |
Why?
|
Hominidae | 1 | 2022 | 68 | 0.210 |
Why?
|
Mutation, Missense | 1 | 2011 | 2564 | 0.200 |
Why?
|
Hearing Loss, Sensorineural | 2 | 2020 | 781 | 0.200 |
Why?
|
Insulin-Like Growth Factor I | 5 | 2019 | 1927 | 0.200 |
Why?
|
Exotropia | 1 | 2022 | 64 | 0.190 |
Why?
|
Lacrimal Duct Obstruction | 3 | 2008 | 53 | 0.190 |
Why?
|
Vision, Binocular | 2 | 2021 | 225 | 0.190 |
Why?
|
Esotropia | 1 | 2022 | 99 | 0.190 |
Why?
|
Bile Acids and Salts | 1 | 2023 | 383 | 0.190 |
Why?
|
Wolfram Syndrome | 1 | 2020 | 15 | 0.190 |
Why?
|
Ophthalmoscopy | 2 | 2014 | 171 | 0.180 |
Why?
|
Adolescent | 13 | 2024 | 87892 | 0.180 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1845 | 0.170 |
Why?
|
Inflammation | 5 | 2021 | 10718 | 0.170 |
Why?
|
Eye Diseases, Hereditary | 1 | 2021 | 118 | 0.170 |
Why?
|
Pain Measurement | 1 | 2010 | 3527 | 0.170 |
Why?
|
Retinal Rod Photoreceptor Cells | 1 | 2001 | 200 | 0.170 |
Why?
|
Nerve Growth Factors | 2 | 2019 | 562 | 0.160 |
Why?
|
Comprehension | 1 | 2024 | 619 | 0.160 |
Why?
|
Angiogenic Proteins | 1 | 2019 | 101 | 0.160 |
Why?
|
Prosthesis Design | 2 | 2020 | 2105 | 0.160 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 25956 | 0.160 |
Why?
|
Placental Insufficiency | 1 | 2019 | 50 | 0.160 |
Why?
|
Lens Subluxation | 1 | 2018 | 23 | 0.160 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2019 | 125 | 0.150 |
Why?
|
Vitrectomy | 2 | 2018 | 391 | 0.150 |
Why?
|
Iris | 1 | 2019 | 231 | 0.150 |
Why?
|
Hemangioma, Capillary | 1 | 2018 | 62 | 0.150 |
Why?
|
Colorado | 1 | 2018 | 164 | 0.150 |
Why?
|
Aptamers, Nucleotide | 1 | 2019 | 163 | 0.150 |
Why?
|
Infant, Extremely Low Birth Weight | 3 | 2019 | 83 | 0.150 |
Why?
|
Incidence | 5 | 2023 | 21272 | 0.150 |
Why?
|
Time Factors | 5 | 2023 | 39872 | 0.140 |
Why?
|
Oculomotor Muscles | 1 | 2021 | 407 | 0.140 |
Why?
|
Tomography, Optical Coherence | 2 | 2021 | 2877 | 0.140 |
Why?
|
Ophthalmic Solutions | 3 | 2016 | 304 | 0.140 |
Why?
|
Eyelid Neoplasms | 1 | 2018 | 89 | 0.140 |
Why?
|
Prospective Studies | 11 | 2023 | 54137 | 0.140 |
Why?
|
Epinephrine | 1 | 2020 | 790 | 0.140 |
Why?
|
Propranolol | 1 | 2018 | 489 | 0.140 |
Why?
|
Rubella Syndrome, Congenital | 1 | 2016 | 12 | 0.140 |
Why?
|
Placenta | 2 | 2019 | 1702 | 0.140 |
Why?
|
Marfan Syndrome | 1 | 2018 | 236 | 0.140 |
Why?
|
Sensory Deprivation | 1 | 2016 | 106 | 0.130 |
Why?
|
Orbital Neoplasms | 1 | 2018 | 221 | 0.130 |
Why?
|
Artificial Intelligence | 2 | 2021 | 2551 | 0.130 |
Why?
|
Retinal Vein Occlusion | 1 | 1997 | 149 | 0.130 |
Why?
|
Telemedicine | 3 | 2020 | 3018 | 0.130 |
Why?
|
Uveitis, Anterior | 1 | 2016 | 102 | 0.130 |
Why?
|
Blepharoptosis | 1 | 2016 | 143 | 0.130 |
Why?
|
Disabled Children | 1 | 2017 | 251 | 0.120 |
Why?
|
Genes, Retinoblastoma | 1 | 2015 | 125 | 0.120 |
Why?
|
Fetal Growth Retardation | 2 | 2019 | 579 | 0.120 |
Why?
|
Blue Toe Syndrome | 1 | 2014 | 4 | 0.120 |
Why?
|
CpG Islands | 1 | 2019 | 1221 | 0.120 |
Why?
|
Eye Enucleation | 1 | 2014 | 128 | 0.120 |
Why?
|
United States | 13 | 2021 | 72136 | 0.120 |
Why?
|
Nigeria | 1 | 2017 | 762 | 0.120 |
Why?
|
Ophthalmic Artery | 1 | 2014 | 58 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2307 | 0.120 |
Why?
|
Prevalence | 3 | 2023 | 15651 | 0.120 |
Why?
|
Eye Proteins | 1 | 2017 | 633 | 0.110 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2019 | 1651 | 0.110 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5797 | 0.110 |
Why?
|
Injections, Intra-Arterial | 1 | 2013 | 182 | 0.110 |
Why?
|
Glioma | 1 | 2008 | 3418 | 0.110 |
Why?
|
Emmetropia | 1 | 2013 | 6 | 0.110 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 859 | 0.110 |
Why?
|
Connective Tissue Diseases | 1 | 2016 | 285 | 0.110 |
Why?
|
Astigmatism | 1 | 2013 | 68 | 0.100 |
Why?
|
Eyelid Diseases | 1 | 2014 | 157 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1240 | 0.100 |
Why?
|
Mitochondrial Diseases | 1 | 2016 | 340 | 0.100 |
Why?
|
Retinal Vein | 2 | 2005 | 47 | 0.100 |
Why?
|
Reproducibility of Results | 6 | 2020 | 20055 | 0.100 |
Why?
|
Refractometry | 1 | 2012 | 57 | 0.100 |
Why?
|
Cell Shape | 1 | 2013 | 371 | 0.100 |
Why?
|
Tuberous Sclerosis | 1 | 2020 | 1030 | 0.100 |
Why?
|
Odds Ratio | 4 | 2019 | 9650 | 0.100 |
Why?
|
Topotecan | 1 | 2012 | 132 | 0.100 |
Why?
|
Retinal Detachment | 1 | 2016 | 427 | 0.100 |
Why?
|
Endophthalmitis | 1 | 2014 | 257 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13591 | 0.100 |
Why?
|
Pedigree | 3 | 2024 | 4578 | 0.100 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 341 | 0.090 |
Why?
|
Algorithms | 5 | 2021 | 13961 | 0.090 |
Why?
|
Logistic Models | 3 | 2015 | 13276 | 0.090 |
Why?
|
Arthritis | 1 | 2016 | 666 | 0.090 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2011 | 313 | 0.090 |
Why?
|
Databases, Factual | 4 | 2019 | 7980 | 0.090 |
Why?
|
Catheterization, Peripheral | 1 | 2014 | 340 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2019 | 3733 | 0.090 |
Why?
|
Hyphema | 1 | 2010 | 26 | 0.090 |
Why?
|
Chorioamnionitis | 1 | 2011 | 156 | 0.090 |
Why?
|
Electroretinography | 2 | 2023 | 517 | 0.090 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2010 | 28 | 0.090 |
Why?
|
Fixation, Ocular | 1 | 2011 | 240 | 0.090 |
Why?
|
Orbital Cellulitis | 1 | 2010 | 33 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2014 | 1177 | 0.080 |
Why?
|
Retinal Neovascularization | 1 | 2012 | 273 | 0.080 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 1402 | 0.080 |
Why?
|
Vincristine | 1 | 2012 | 1038 | 0.080 |
Why?
|
Mutation | 4 | 2020 | 29915 | 0.080 |
Why?
|
Cell Count | 1 | 2013 | 1835 | 0.080 |
Why?
|
Genes, Dominant | 1 | 2011 | 862 | 0.080 |
Why?
|
Disease Progression | 3 | 2018 | 13468 | 0.080 |
Why?
|
Skin Ulcer | 1 | 2010 | 129 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1780 | 0.080 |
Why?
|
Corneal Diseases | 1 | 2014 | 536 | 0.080 |
Why?
|
Ocular Hypertension | 1 | 2010 | 206 | 0.080 |
Why?
|
False Positive Reactions | 2 | 2012 | 956 | 0.080 |
Why?
|
Microscopy | 1 | 2013 | 884 | 0.080 |
Why?
|
Massachusetts | 1 | 2021 | 8823 | 0.080 |
Why?
|
Remote Consultation | 1 | 2010 | 234 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1829 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14490 | 0.070 |
Why?
|
Eye Infections, Bacterial | 1 | 2010 | 239 | 0.070 |
Why?
|
Cellulitis | 1 | 2008 | 207 | 0.070 |
Why?
|
Glucocorticoids | 1 | 2016 | 2144 | 0.070 |
Why?
|
Autistic Disorder | 1 | 2016 | 1216 | 0.070 |
Why?
|
Genetic Linkage | 1 | 2011 | 2381 | 0.070 |
Why?
|
Young Adult | 3 | 2023 | 58808 | 0.070 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2218 | 0.070 |
Why?
|
Carbon Dioxide | 1 | 2010 | 1146 | 0.070 |
Why?
|
Psychomotor Performance | 1 | 2014 | 1878 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 23884 | 0.060 |
Why?
|
Face | 1 | 2012 | 1017 | 0.060 |
Why?
|
Pregnancy | 7 | 2019 | 29742 | 0.060 |
Why?
|
Doxorubicin | 1 | 2012 | 2209 | 0.060 |
Why?
|
Retinal Artery | 1 | 2005 | 109 | 0.060 |
Why?
|
DNA Methylation | 1 | 2019 | 4373 | 0.060 |
Why?
|
Brain Diseases | 1 | 2014 | 1541 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15225 | 0.060 |
Why?
|
Heterozygote | 1 | 2011 | 2797 | 0.060 |
Why?
|
Nutritional Status | 1 | 2013 | 1607 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3671 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4603 | 0.060 |
Why?
|
Craniofacial Abnormalities | 1 | 2007 | 315 | 0.060 |
Why?
|
Ciliary Arteries | 1 | 2024 | 19 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2016 | 12262 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2048 | 0.060 |
Why?
|
Child Development | 1 | 2015 | 2285 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7843 | 0.060 |
Why?
|
Pediatrics | 1 | 2018 | 3587 | 0.050 |
Why?
|
Oximetry | 1 | 2006 | 460 | 0.050 |
Why?
|
Risk | 1 | 2015 | 9599 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2011 | 4106 | 0.050 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2010 | 1489 | 0.050 |
Why?
|
Tonometry, Ocular | 1 | 2024 | 235 | 0.050 |
Why?
|
Anesthetics, Local | 1 | 2010 | 1000 | 0.050 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2015 | 2496 | 0.050 |
Why?
|
Social Conditions | 1 | 2023 | 119 | 0.050 |
Why?
|
Equipment Design | 1 | 2010 | 3507 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5816 | 0.050 |
Why?
|
Regression Analysis | 1 | 2011 | 6354 | 0.050 |
Why?
|
Sensitivity and Specificity | 4 | 2015 | 14641 | 0.050 |
Why?
|
Adult | 7 | 2023 | 219935 | 0.050 |
Why?
|
Surgical Flaps | 1 | 2010 | 1669 | 0.050 |
Why?
|
Nervous System Diseases | 1 | 2011 | 1647 | 0.050 |
Why?
|
Registries | 3 | 2023 | 8175 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8611 | 0.050 |
Why?
|
Reading | 1 | 2024 | 529 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2005 | 706 | 0.050 |
Why?
|
Treatment Failure | 1 | 2007 | 2640 | 0.050 |
Why?
|
Base Sequence | 1 | 2011 | 12436 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 1997 | 4673 | 0.040 |
Why?
|
Ultrasonography, Prenatal | 1 | 2008 | 1745 | 0.040 |
Why?
|
Syndrome | 1 | 2007 | 3262 | 0.040 |
Why?
|
Dark Adaptation | 1 | 2001 | 221 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11152 | 0.040 |
Why?
|
Intensive Care Units, Neonatal | 2 | 2020 | 833 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5404 | 0.040 |
Why?
|
Sensory Thresholds | 1 | 2001 | 377 | 0.040 |
Why?
|
Models, Biological | 1 | 2016 | 9460 | 0.040 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2011 | 2125 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12951 | 0.040 |
Why?
|
Crystallins | 1 | 1999 | 75 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2014 | 36284 | 0.040 |
Why?
|
Sutures | 1 | 2021 | 293 | 0.040 |
Why?
|
Vision Tests | 1 | 2019 | 158 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 441 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 17617 | 0.040 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1999 | 330 | 0.040 |
Why?
|
Lasers | 1 | 2023 | 952 | 0.040 |
Why?
|
Acute Disease | 2 | 2016 | 7225 | 0.040 |
Why?
|
Genes, Recessive | 1 | 2020 | 626 | 0.040 |
Why?
|
Anterior Chamber | 1 | 2018 | 194 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1999 | 763 | 0.040 |
Why?
|
Glaucoma, Neovascular | 1 | 1997 | 36 | 0.040 |
Why?
|
Aged, 80 and over | 1 | 2022 | 58683 | 0.040 |
Why?
|
Retina | 2 | 2020 | 2635 | 0.030 |
Why?
|
Cognition | 1 | 2014 | 6953 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10748 | 0.030 |
Why?
|
Safety | 1 | 2001 | 1147 | 0.030 |
Why?
|
Age of Onset | 2 | 2020 | 3298 | 0.030 |
Why?
|
Fundus Oculi | 1 | 1997 | 540 | 0.030 |
Why?
|
Protein Structure, Secondary | 1 | 1999 | 1229 | 0.030 |
Why?
|
Depth Perception | 1 | 2016 | 94 | 0.030 |
Why?
|
Language | 1 | 2024 | 1532 | 0.030 |
Why?
|
Pain | 1 | 2010 | 5065 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 697 | 0.030 |
Why?
|
Coloboma | 1 | 2014 | 59 | 0.030 |
Why?
|
ROC Curve | 2 | 2016 | 3563 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 184 | 0.030 |
Why?
|
S100 Proteins | 1 | 2014 | 218 | 0.030 |
Why?
|
Point Mutation | 1 | 1999 | 1593 | 0.030 |
Why?
|
Blood Proteins | 1 | 2019 | 1173 | 0.030 |
Why?
|
Cryotherapy | 1 | 2014 | 161 | 0.030 |
Why?
|
Intelligence Tests | 1 | 2014 | 500 | 0.030 |
Why?
|
Keratins | 1 | 2014 | 497 | 0.030 |
Why?
|
Life Tables | 1 | 2013 | 365 | 0.030 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2014 | 550 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15773 | 0.030 |
Why?
|
Sweden | 1 | 2015 | 1376 | 0.030 |
Why?
|
Choroid | 1 | 2014 | 349 | 0.030 |
Why?
|
Intraoperative Complications | 1 | 2019 | 1184 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2018 | 15785 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3615 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1705 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11709 | 0.020 |
Why?
|
Reoperation | 1 | 2001 | 4282 | 0.020 |
Why?
|
Genetic Testing | 1 | 2024 | 3530 | 0.020 |
Why?
|
Skin Care | 1 | 2010 | 57 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7818 | 0.020 |
Why?
|
Canada | 1 | 2015 | 2111 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 41256 | 0.020 |
Why?
|
Mucin-1 | 1 | 2014 | 539 | 0.020 |
Why?
|
Sentinel Surveillance | 1 | 2010 | 293 | 0.020 |
Why?
|
Eyelids | 1 | 2010 | 277 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 1997 | 2016 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29557 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2016 | 1793 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 2009 | 463 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 20500 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2009 | 540 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2010 | 2497 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2413 | 0.020 |
Why?
|
Trans-Activators | 1 | 2014 | 2860 | 0.010 |
Why?
|
Erythropoietin | 1 | 2009 | 719 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7338 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4406 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1632 | 0.010 |
Why?
|
Animals | 4 | 2022 | 167768 | 0.010 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2009 | 1373 | 0.010 |
Why?
|
Nuclear Family | 1 | 1999 | 313 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2010 | 12096 | 0.010 |
Why?
|
Cattle | 1 | 1999 | 3845 | 0.010 |
Why?
|
Exons | 1 | 1999 | 2387 | 0.010 |
Why?
|
Diet | 1 | 2009 | 8005 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1999 | 6068 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 8945 | 0.000 |
Why?
|
Models, Molecular | 1 | 1999 | 5410 | 0.000 |
Why?
|
Polymorphism, Genetic | 1 | 1999 | 4284 | 0.000 |
Why?
|
Brain | 1 | 2014 | 26947 | 0.000 |
Why?
|
Genotype | 1 | 1999 | 12945 | 0.000 |
Why?
|